Plasma exosome-derived fragile-site associated tumor suppressor is a powerful predictor of prognosis in patients with ovarian cancer

  • Renjing Ju Department of Laboratory Medicine, Wuxi Second People's Hospital, Jiangsu, China
  • Xiaochun Chen Department of Laboratory Medicine, Taizhou Second People's Hospital, Taizhou, Jiangsu, China
  • Shiliang Zhang Department of Laboratory Medicine, Wuxi Fifth People's Hospital, Jiangsu, China
  • Bin Liu Department of Laboratory Medicine, Wuxi Fifth People'sHospital, Jiangsu, China
  • Hao Pei Department of Laboratory Medicine, Wuxi Fifth People's Hospital, Jiangsu, China
  • Fan Tu Department of Laboratory Medicine, Wuxi Fifth People's Hospital, Jiangsu, China
  • Jun Liu Department of Laboratory Medicine, Wuxi Fifth People's Hospital, Jiangsu, China
  • Hao Yu Department of Interventional Oncology, Wuxi Fifth People's Hospital,, Jiangsu, China
Keywords: Fragile-site associated tumor suppressor (FATS), ovarian cancer, exosomes, prognosis, predictive value

Abstract

Objective: To investigate the levels of plasma exosome-derived fragile-site associated tumor suppressor (FATS) and evaluate its predictive ability in ovarian cancer (OC) patients.

Patients and Methods: Exosome-rich fractions were isolated from the plasma of enrolled 90 patients with OC. The levels of plasma exosome-derived FATS were detected with ELISA.

Results: The levels of exosome-derived FATS in OC patient were significantly lower than in healthy controls (P < 0.001). The levels of plasma exosome-derived FATS were obviously higher in OC patients with low grade (1/2), FIGO stages I/II than high grade (3/4), stages III/ IV disease (P = 0.003; P < 0.001). The levels of plasma exosome-derived FATS were significantly higher in OC patients with no lymph node metastasis, no ascites than those with lymph node metastasis, ascites (both P < 0.001). The levels of plasma exosome-derived FATS were obviously higher in OC patients with CA-125 less than 35U/ml than more than 35U/ml (P < 0.001). Among all enrolled OC patients, both 5-DFS and 5-OS were shorter in patients who had low plasma exosome-derived FATS levels than that high levels (both P < 0.001). The AUROC of plasma exosome-derived FATS were 0.85(95% CI: 0.76-0.91) for 5-DFS, 0.91(95% CI: 0.83-0.96) for 5-OS prediction in patients with OC, respectively.

Conclusions: Plasma exosome-derived FATS levels in OC patient were significantly down-regulated. Low levels of plasma exosome-derived FATS had close relationship with FIGO stages I/II, low grade, ascites, higher levels of CA-125, lymph node metastasis and prognosis of OC patients. Our findings may provide a new strategy in treating OC.

Downloads

Download data is not yet available.
Plasma exosome-derived fragile-site associated tumor suppressor is a powerful predictor of prognosis in patients with ovarian cancer
Published
2021-09-07
How to Cite
1.
Ju R, Chen X, Zhang S, Liu B, Pei H, Tu F, Liu J, Yu H. Plasma exosome-derived fragile-site associated tumor suppressor is a powerful predictor of prognosis in patients with ovarian cancer. Bosn J of Basic Med Sci [Internet]. 2021Sep.7 [cited 2021Sep.18];. Available from: https://www.bjbms.org/ojs/index.php/bjbms/article/view/6404
Section
Translational and Clinical Research

Funding data